SOURCE: Helix BioPharma Corp.

Helix BioPharma Corp.

October 19, 2016 18:42 ET

Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy

CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer

TORONTO, ON--(Marketwired - Oct 19, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CAR-T cells harboring camelid single domain antibody as targeting agent to CEACAM6 antigen in pancreatic cancer will be presented on Friday, October 21, 2016 during the AACR Conference on Tumor Immunology and Immunotherapy which is taking place on October 20th through to the 23rd, 2016 at the Boston Marriott Copley Place in Boston, Massachusetts.

The poster describes the Company's on-going work in applying camelid single domain antibody in making chimeric antigen receptor T cells ("CAR-T"). The poster provides preliminary data showing that a CAR-T construct based on camelid single domain antibody that targets CEACAM6 is effective in an animal pancreatic tumor model.

"We are delighted to report on our continuing progress with CAR-T in solid tumor. The data we will be presenting at the conference along with some of the other research we are currently conducting, we believe will form the basis upon which the Company will be able to build a pipeline of therapeutic candidates for solid tumor using CAR-T technology," said Heman Chao, Chief Scientific Officer.

The poster will be shown on Friday, October 21, 2016 during Poster Session A at the Back Bay Conference Room Boston Marriott Copley Place. A copy of the poster will be available on the Company's website (http://www.helixbiopharma.com).

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential of using camelid single domain antibody in making CAR-T for pancreatic cancer, the advancing of the Company's first CAR-T solid tumor candidate toward clinical testing, the building of a pipeline of therapeutic candidates for solid tumor using CAR-T technology, which may be identified by words including, without limitation, "believes", "will", "may", "anticipated", "intended", "build", "effective", "continuing progress" and other similar expressions, are intended to provide information about management's current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include those described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Contact Information

  • Investor Relations
    Helix BioPharma Corp.
    21 St. Clair Avenue East, Suite 1100
    Toronto, Ontario, M4T 1L9
    Tel: 416 925-3232
    Email: ir@helixbiopharma.com